IMVT
Immunovant·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
IMVT fundamentals
Immunovant (IMVT) released its earnings on Nov 10, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.73 (YoY +1.35%), met estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.73
+1.35%
Report date
Nov 10, 2025
IMVT Earnings Call Summary for Q2,2026
- DM Market Leader: Brepocitinib Phase III data positions as first novel oral DM therapy with 30mg dose showing 1/3 patients off steroids. NDA filing Q1 2026.
- Graves’ Innovation: Batoclimab delivers 6-month remission in 81% of patients, with 75% off/low ATD use. FcRn mechanism validated by argenx’s VYVGART follow-on.
- Litigation Catalyst: Moderna trial March 2026; favorable Pfizer ruling. Global LNP enforcement could unlock $5B+ damages.
- Pipeline Expansion: 11 registrational trials across 6 indications. Sjögren’s Phase II targeting ESSDAI; Pulmovant PH-ILD data H2 2026.
- Capital Strength: $4.4B cash to fund pipeline through profitability; $500M buyback authorization.
EPS
Revenue
Revenue & Expenses
Key Indicators
Immunovant (IMVT) key financial stats and ratios, covering profitability, financial health, and leverage.
Immunovant (IMVT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Immunovant (IMVT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Immunovant (IMVT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Immunovant (IMVT) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Immunovant (IMVT) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What were the key takeaways from Immunovant's earnings call?What is Immunovant's latest dividend and current dividend yield?What guidance did Immunovant's management provide for the next earnings period?What does Immunovant do and what are its main business segments?What factors drove the changes in Immunovant's revenue and profit?Did Immunovant beat or miss consensus estimates last quarter?What were the key takeaways from Immunovant’s earnings call?What is the revenue and EPS growth rate for Immunovant year over year?
